Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Cachexia / Wasting Syndrome

Military Diet: Health Risks

Cachexia and Cancer

Does Cinnamon Help with Weight Loss?

How Does Semaglutide Work to Lose Weight?

How Oral GLP-1 Drugs Work For Weight Loss

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

The Natural Molecule That Could Rival Ozempic

Mental Health Disorders, Weight Gain, and Exercise

Weight Loss After Bariatric Surgery

See more featured articles »

Circadian Rhythm and Weight Loss

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Vegetarian Diets for Weight Loss

Semaglutide and Weight Loss in Menopause

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Wegovy: A Breakthrough in Weight Loss?

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Unexplained Weight Loss: When It Might Signal a Health Problem

Latest Weight Loss News and Research

Losing weight is one thing. Keeping your muscle is another, experts say

The International Society of Sports Nutrition (ISSN) position stand concludes that sustained calorie restriction drives weight loss, while adequate protein intake and resistance training help preserve lean mass. Reviewing intermittent fasting, ketogenic diets, and other dietary approaches, the authors emphasize individualized nutrition plans, body composition, and sustainable weight management rather than rapid weight loss alone.

14 Oct 2026

Doctors avoided two common words when talking about weight with patients

Researchers analyzed 123 recorded primary care consultations involving adults with type 2 diabetes and elevated BMI, finding that weight was discussed in just 39% of visits. Clinicians avoided potentially stigmatizing terms such as "overweight" and "obesity," while weight-related conversations occurred more frequently among patients taking GLP-1 receptor agonists.

13 Oct 2026

Three months of yoga before surgery revealed a surprising difference in stress hormones

In a non-randomized study of 40 adults with severe obesity awaiting bariatric surgery, researchers found significantly lower plasma noradrenaline levels in yoga participants than in controls after adjusting for baseline measurements. The researchers detected no significant DNA methylation changes in three inflammatory genes and found no clear psychological or metabolic benefits.

12 Oct 2026

Diet drinks showed no clear weight-loss edge over water after two years

In a two-year randomized trial combining assisted weight management with an unassisted follow-up year, completers maintained average weight losses of 4.8 kg with diet drinks and 3.7 kg with water. Researchers found no significant difference between groups, but fewer than half of the 493 participants completed follow-up.

11 Oct 2026

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.

11 Oct 2026

Routine blood test may offer clues to future dementia risk

A common blood test already carried out during routine health checks may contain clues about a person's long-term risk of dementia, according to research being presented at the ECNP Congress in Munich and recently published in the Journal of Alzheimer's Disease.

9 Oct 2026

Nerve-stimulation device enters human trials for cancer-related cachexia

The Terasaki Institute for Biomedical Innovation announced today that OnVagus, a medical device company incubating at the Institute, has received institutional and regulatory approval to begin the first human trial of its noninvasive nerve-stimulation device for patients experiencing cancer-related wasting.

7 Oct 2026

Structured support may slow weight regain after stopping GLP-1 drugs

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors-commonly leading to rapid weight regain.

7 Oct 2026

Does extra protein protect aging muscle during fasting?

A randomized trial found that alternate-day fasting reduced weight in older men, while added protein and leucine did not prevent lean mass loss.

7 Oct 2026

SGLT2 inhibitors reduce inflammatory cells linked to heart disease

For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight loss and glucose lowering benefits, has been shown to also reduce inflammatory cells in the blood known to cause cardiovascular disease.

6 Oct 2026

Overweight dementia patients likely to live longer than normal weight peers

People who are overweight or obese when they are diagnosed with dementia are likely to live longer than those in a normal weight range, according to a new study by Columbia University Mailman School of Public Health and NYU School of Global Public Health.

6 Oct 2026

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

Lab-grown human pituitary cells work and survive after transplantation into a primate

Researchers in Japan have transplanted pituitary tissue grown from human stem cells into a primate whose pituitary gland had been surgically removed, successfully restoring critical hormone signals.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026